Johnson & Johnson Form 4 Filings

JOHNSON & JOHNSON (symbol: JNJ) is the issuer of record for a Form 4 filing submitted to the SEC. Woods Eugene A. reported acquisition or exercise transactions in this Form 4 filing.

JOHNSON & JOHNSON (JNJ) reported that director Eugene A. Woods received a grant of 135.717 Deferred Share Units (DSUs) on September 8, 2026 as part of his deferred cash retainer under the company’s Deferred Fee Plan for Directors, bringing his directly held DSUs to 6,578.771.

The DSUs, each linked in value to one share of common stock, will be settled in cash when his service as a director ends and include dividend equivalent rights that accrue based on Johnson & Johnson’s quarterly dividends.

JOHNSON & JOHNSON (symbol: JNJ) is the issuer of record for a Form 4 filing submitted to the SEC. HEWSON MARILLYN A reported acquisition or exercise transactions in this Form 4 filing.

JOHNSON & JOHNSON (JNJ) reported that director Marillyn A. Hewson received a grant of 180.956 Deferred Share Units (DSUs) on September 8, 2026 as a deferred cash retainer under the company’s Deferred Fee Plan for Directors. After this award, she holds 16,049.417 DSUs directly.

The DSUs, including associated dividend equivalent rights, are to be settled in cash upon termination of her directorship, with each DSU tied to the fair market value of one share of Johnson & Johnson common stock on the business day prior to settlement.

JOHNSON & JOHNSON (JNJ) executive Timothy Schmid, EVP and Worldwide Chair of MedTech, reported exercising employee stock options and selling the resulting common shares on September 2, 2026. He exercised options for 11,070 shares with an exercise price of $131.94 per share and for 22,527 shares with an exercise price of $151.41 per share, both granted under the company’s Long-Term Incentive Plan and expiring in 2029 and 2030, respectively. He acquired an equal number of common shares from these exercises and then sold 11,070 shares and 22,527 shares of common stock the same day at a reported price of $274.74 per share, resulting in a net sale of 33,597 shares. Indirect holdings reported as of the most recent plan reporting date include 758 shares through a 401(k) plan and 46 shares through an employee stock ownership plan. No Rule 10b5-1 trading plan is indicated.

JOHNSON & JOHNSON (JNJ) executive Jennifer L. Taubert (EVP, WWC. Innovative Medicine) reported an exercise-and-sale transaction involving 15,000 shares. She exercised 15,000 Employee Stock Options to acquire 15,000 shares of Common Stock at $115.67 per share, then sold 15,000 shares of Common Stock at a weighted average price of $263.36 per share in trades between $263.30 and $263.48. Following the option exercise, she held 28,712 derivative securities (stock options) of the issuer directly.

Johnson & Johnson CEO and Chairman Joaquin Duato reported a series of transactions on August 13, 2026. He exercised 123,291 Employee Stock Options at an exercise price of $115.67 per share, receiving an equal number of common shares. On the same date he sold 20,976 shares at $262.00 per share and 102,315 shares at $261.00 per share. Indirect holdings reported include 1,018 shares held through a 401(k) plan and 30,852 shares held by his spouse, with the 401(k) amount including shares accrued via dividend reinvestment under the Johnson & Johnson Savings Plan.

Johnson & Johnson CEO and chairman Joaquin Duato reported selling 48,480 shares of common stock on August 5, 2026, in two open-market transactions at weighted average prices of $258.056 and $258.739. He continues to report indirect holdings of 1,018 shares via a 401k plan and 30,852 shares held by his spouse.

Johnson & Johnson executive Elizabeth Forminard, EVP and Chief Legal Officer, exercised employee stock options covering 9,344 shares of common stock on August 6, 2026. These options, granted under the company’s Long-Term Incentive Plan, had an exercise price of $131.94 per share and an expiration date of February 11, 2029.

On the same date, she acquired 9,344 shares of common stock through the option exercise and then sold a total of 15,918 shares of common stock in open market or private transactions, including 9,344 shares at $257.755 per share and 6,574 shares at $255.932 per share. After the exercise, the reported balance for this specific stock option award was 0 shares.

Vanessa Broadhurst, EVP, Global Corp Affairs at Johnson & Johnson, exercised employee stock options for 11,129 and 11,925 shares of Common Stock on July 20, 2026 at exercise prices of $129.5100 and $131.9400 per share, then sold 23,054 shares in transactions described as open market or private at a weighted average price of $251.2660 per share. These options were awarded under the issuer's Long-Term Incentive Plan and become exercisable on the third anniversary of the grant date.

JOHNSON & JOHNSON executive Kathryn E. Wengel reported an exercise-and-sell transaction in company stock. On June 11, 2026, she exercised 10,000 employee stock options with an exercise price of $115.67 per share and acquired the same number of common shares.

That same day, she sold 10,000 common shares in open-market transactions, with trades executed at prices between $240.14 and $240.19, according to a weighted-average price footnote. After these transactions, she directly owned 114,287.8735 shares of common stock and held 32,965 stock options outstanding.

She also reported indirect holdings of 281 shares through an ESOP position and 90 shares via a 401(k) plan as of the plan’s May 31, 2026 reporting date.

Woods Eugene A. reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Eugene A. Woods received 161.089 Deferred Share Units as a compensation-related award tied to deferral of his cash retainer under the company’s Deferred Fee Plan for Directors. Following this grant, he holds a total of 6,411.959 Deferred Share Units. These units, including dividend equivalent rights, are to be settled in cash upon the end of his board service and mirror the value of one common share each at settlement.

Johnson & Johnson director Daniel E. Pinto received a grant of 134.241 Deferred Share Units on June 9, 2026, tied to a reference price of $232.79 per unit. After this award, he holds 2,320.824 Deferred Share Units.

The units were acquired by deferring his cash retainer under the company’s Amended and Restated Deferred Fee Plan for Directors. These Deferred Share Units are settled in cash when his board service ends and each unit reflects the fair market value of one share of common stock at settlement, including dividend equivalent rights credited over time.

HEWSON MARILLYN A reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Marillyn A. Hewson reported receiving 214.786 Deferred Share Units on June 9, 2026 as a grant under the company’s Amended and Restated Deferred Fee Plan for Directors. These units represent deferred cash retainers and are to be settled in cash when her board service ends, bringing her total Deferred Share Units to 15,791.877, including amounts accrued as dividend equivalent rights.

JOHNSON & JOHNSON EVP John C. Reed reported routine equity compensation activity involving restricted share units (RSUs) and tax withholding. On May 1, 2026, RSUs covering 25,255 shares of Common Stock vested and were exercised into shares.

To cover taxes due at vesting, 11,002 shares of Common Stock were withheld at a reference price of $229.85 per share. After these transactions, Reed directly owned 24,911 shares of Johnson & Johnson Common Stock. This reflects RSU vesting and related tax withholding, not an open-market purchase or sale.

Woods Eugene A. reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Eugene A. Woods received 975 Deferred Share Units (DSUs) as a grant under the company’s Amended and Restated Deferred Fee Plan for Directors. These DSUs are to be settled in cash when his directorship ends, with each DSU equal to the fair market value of one Johnson & Johnson common share on the settlement date.

After this award, Woods holds a total of 6,215.094 DSUs, including dividend equivalent rights that accrue on DSUs in connection with the company’s quarterly dividend. The transaction reflects compensation in the form of deferred, cash-settled, share-linked units rather than an open-market stock purchase or sale.

Johnson & Johnson director Nadja West received a grant of 975 Deferred Share Units (DSUs) on April 23, 2026. These DSUs were acquired under the company’s Amended and Restated Deferred Fee Plan for Directors at a price of $0.00 per unit.

Following this award, West holds a total of 7,730.0491 DSUs. Each DSU will be settled in cash upon the end of her board service, with each unit representing the fair market value of one share of Johnson & Johnson common stock on the settlement date. The holding also includes dividend equivalent rights that accrue as the company pays its quarterly dividend.

Johnson & Johnson director Mark A. Weinberger received a grant of 975 Deferred Share Units (DSUs) on Common Stock, reported as a compensation-related acquisition at a price of $0.00 per unit. After this grant, he holds a total of 12,010.408 DSUs directly.

According to the plan terms, these DSUs are to be settled in cash when his service as a director ends, with each DSU valued at the fair market value of one share of Common Stock on the settlement date. The reported holdings also include dividend equivalent rights that accrue on DSUs in line with Johnson & Johnson’s quarterly dividend.

Pinto Daniel E reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Daniel E. Pinto received a grant of 1,712 Deferred Share Units (DSUs). These DSUs were awarded under the company’s Amended and Restated Deferred Fee Plan for Directors and are a form of non-cash director compensation.

After this grant, Pinto holds a total of 2,174.069 DSUs. According to the disclosure, these DSUs will be settled in cash when his board service ends, with each unit representing the fair market value of one share of Johnson & Johnson common stock on the settlement date. The total also reflects dividend equivalent rights that accrue on DSUs in connection with the company’s quarterly dividends.

Johnson & Johnson director John G. Morikis received a grant of 1,540 Deferred Share Units (DSUs) as compensation. These DSUs were acquired at a stated price of $0.00 per unit and are tied to Johnson & Johnson common stock for value reference.

According to the plan terms, the DSUs will be settled in cash after Morikis’ service as a director ends, with each unit worth the fair market value of one share of common stock on the settlement date. After this grant, he holds 1,540 DSUs related to this plan.

McClellan Mark B. reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Mark B. McClellan received a grant of 975 Deferred Share Units (DSUs) tied to the company’s common stock. These DSUs were awarded under the Amended and Restated Deferred Fee Plan for Directors and increase his direct DSU holdings to 21,278.593 units.

The DSUs will be settled in cash when his board service ends, with each unit representing the fair market value of one Johnson & Johnson common share on the settlement date. The award also includes dividend equivalent rights that accrue on DSUs in line with the company’s quarterly dividend.

Joly Hubert reported acquisition or exercise transactions in this Form 4 filing.

JOHNSON & JOHNSON director Hubert Joly received a new equity-based award. On this Form 4, he was granted 975 Deferred Share Units (DSUs) tied to Johnson & Johnson common stock, increasing his DSU holdings to 9,183.605 units.

The DSUs were awarded at a stated price of $0.00 per unit under the company’s Amended and Restated Deferred Fee Plan for Directors. According to the disclosure, these DSUs will be settled in cash when Joly’s board service ends, with each DSU representing the fair market value of one share of common stock on the settlement date and including dividend equivalent rights that accrue with the company’s quarterly dividends.

Johnson Paula A reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Paula A. Johnson received a grant of 975 Deferred Share Units (DSUs) tied to the company’s common stock. These DSUs were awarded at no cash cost and will be settled in cash when her board service ends, based on the then-current share value.

After this grant and related dividend-equivalent accruals, she holds a total of 5,359.3973 DSUs, which track the value of Johnson & Johnson common stock but do not involve immediate share purchases or sales.

HEWSON MARILLYN A reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Marillyn A. Hewson received 975 Deferred Share Units (DSUs) as a grant under the company’s Amended and Restated Deferred Fee Plan for Directors. The DSUs were awarded at $0.00 per unit and are classified as derivative securities.

After this grant, Hewson holds a total of 15,487.939 DSUs. According to the plan terms, these DSUs will be settled in cash when her service as a director ends, with each DSU representing the fair market value of one share of Johnson & Johnson common stock on the settlement date. The holdings also include dividend equivalent rights that accrue on DSUs in line with the company’s quarterly dividend.

Doudna Jennifer A reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Jennifer A. Doudna received a grant of 975 Deferred Share Units (DSUs). These DSUs were awarded under the company’s Amended and Restated Deferred Fee Plan for Directors.

The DSUs are to be settled in cash when her board service ends, with each DSU equal to the fair market value of one Johnson & Johnson common share on the settlement date. Following this grant, she holds a total of 10,899.1714 DSUs, including units attributable to dividend equivalent rights that accrue in connection with the company’s quarterly dividend.

Beckerle Mary C reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Mary C. Beckerle received 975 Deferred Share Units (DSUs) as a grant under the company’s Amended and Restated Deferred Fee Plan for Directors. After this award, she holds a total of 16,797.7393 DSUs. These DSUs will be settled in cash upon the end of her board service, with each DSU reflecting the fair market value of one J&J common share on the settlement date. The position also includes dividend equivalent rights that accrue on DSUs in line with Johnson & Johnson’s quarterly dividends.

HEWSON MARILLYN A reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Marillyn A. Hewson reported routine compensation-related awards of Deferred Share Units (DSUs), not open-market stock trades. On March 10, 2026, she received 206.4920 DSUs valued at $242.1400 each, bringing her holdings to 14512.9400 DSUs.

The filing also reflects a prior DSU award of 75.2560 units on March 4, 2025 at $166.1000 per unit. These DSUs represent deferred cash retainers under the company’s Deferred Fee Plan for Directors, are settled in cash when her board service ends, and track the fair market value of one share of common stock plus dividend equivalents.

Pinto Daniel E reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Daniel E. Pinto received a grant of 129.058 Deferred Share Units, credited at a reference price of $242.14 per unit, in connection with deferring his cash director retainer. These units track the value of one common share each and are to be settled in cash when his board service ends, bringing his total deferred units to 462.069 including dividend-equivalent accruals.

Johnson & Johnson director Eugene A. Woods received a grant of deferred share units as part of his board compensation. On this date, he acquired 154.869 Deferred Share Units (DSUs), each valued at 242.1400 per unit, bringing his total DSU balance to 5,240.094 units.

The DSUs represent deferred cash retainer fees under the company’s Amended and Restated Deferred Fee Plan for Directors and are to be settled in cash when his directorship ends. Each DSU tracks the fair market value of one share of Johnson & Johnson common stock, and the balance includes dividend equivalent rights credited on outstanding DSUs.

Johnson & Johnson executive Robert J. Decker, VP Corporate Controller, exercised employee stock options for 4,075 shares of common stock on February 27, 2026 and immediately received those shares at an exercise price of $115.67 per share. He then sold 4,075 shares of common stock the same day in an open-market transaction at an average price of $247.87 per share, leaving him with 23,682 shares of common stock held directly.

In addition to his direct holdings, Decker is reported as having 134 shares of common stock held indirectly through an ESOP under the Johnson & Johnson Savings Plan and 646 shares held indirectly through a 401(k) plan, both as of the plans’ most recent reporting date of February 28, 2026.

Johnson & Johnson EVP Timothy Schmid reported an open-market sale of 1,322 shares of common stock at $245.66 per share on February 20, 2026. After this transaction, he directly held 25,447 shares of Johnson & Johnson.

He also reported indirect holdings of 46 shares through an ESOP under the Johnson & Johnson Savings Plan and 745 shares through a 401(k), both based on the plan’s most recent reporting date of January 31, 2026.

Johnson & Johnson executive James D. Swanson reported a series of equity compensation transactions and related share sales. On February 13–17, 2026, he exercised employee stock options, restricted share units (RSUs), and performance share units (PSUs) into Johnson & Johnson common stock, with prices on certain option exercises around $162.75–$165.89 per share.

Swanson then conducted open-market sales totaling 62,080 shares of common stock at weighted average prices around $242.70–$243.76, while additional shares were withheld to cover tax obligations upon RSU and PSU vesting. Following these transactions, he directly owned 25,698.131 shares of Johnson & Johnson common stock.

Separately, on February 15, 2026, he received new equity awards under the company’s Long-Term Incentive Plan, including 19,449 employee stock options and 1,397 RSUs, which vest in three equal annual installments and convert into common stock on a one-for-one basis upon vesting.

Johnson & Johnson executive Kathryn E. Wengel, EVP and Chief TO and Risk Officer, reported multiple equity compensation transactions. She exercised vested restricted share units and performance share units into common stock on February 13 and 15, 2026, and received new grants of restricted share units and employee stock options under the company’s Long-Term Incentive Plan.

On those dates she acquired common shares through derivative exercises and awards, while a portion of the resulting shares was withheld at prices of $243.45 and $244.55 per share to cover tax obligations, which is disclosed as share dispositions. After these transactions, she held 113,977.8735 common shares directly, plus additional indirect holdings in the Johnson & Johnson Savings Plan and ESOP.

Johnson & Johnson EVP and Chief HR Officer Kristen Mulholland reported equity compensation activity involving restricted share units, performance share units, stock options, and common stock. On February 15, 2026 she received grants of 20,322 employee stock options and 1,459 restricted share units, all at a stated price of $0.0000 per unit, under the company’s Long-Term Incentive Plan.

On the same date, previously granted restricted share units converted into 419 and 575 shares of common stock, increasing her direct holdings. Some of these new shares were withheld at prices of about $243.45 per share to cover tax obligations, reported with transaction code F as tax-withholding dispositions, rather than open-market sales.

On February 13, 2026, earlier grants of restricted share units and performance share units from prior years also converted into common stock. Those conversions added blocks of 410 and 3,602 common shares, followed by additional F-coded dispositions at around $244.55 per share to satisfy taxes due upon vesting. After these transactions, she continued to hold common stock directly, with the filing showing updated post-transaction balances for each line item.

JOHNSON & JOHNSON Executive VP and CFO Joseph J. Wolk reported multiple equity award transactions and sales. He exercised stock options, performance share units, and restricted share units into common stock on February 13, 15, and 17, 2026, and received new grants of 53,793 employee stock options and 3,863 restricted share units under the company’s long‑term incentive plan.

On February 17, 2026, he sold 89,654 shares of common stock in open‑market transactions and also disposed of shares to cover tax obligations upon vesting of awards. After these transactions, direct ownership entries show 14,000 common shares, alongside indirect holdings of 68,835 shares in a spousal lifetime access trust and 2,173 shares in a 401(k) plan.

Johnson & Johnson VP Corporate Controller Robert J. Decker reported multiple equity compensation transactions. On February 15, 2026, he received a grant of 4,871 employee stock options and 700 restricted share units (RSUs) under the company’s Long-Term Incentive Plan, each RSU representing the right to one common share upon vesting.

On February 13 and 15, 2026, previously awarded RSUs and performance share units vested and were converted to common stock through several derivative exercises coded “M.” To cover tax obligations on these vestings, a portion of the resulting shares (including amounts coded “F” at prices around $243.45–$244.55) was withheld and disposed of as tax-withholding transactions, not open-market sales. After these transactions, he reported direct ownership of common stock plus additional indirect holdings through an ESOP and 401(k) plan.

Johnson & Johnson executive John C. Reed, EVP of Innovative Medicine R&D, reported multiple equity compensation transactions. He exercised employee stock options and restricted share units into common stock and received new awards of 49,382 employee stock options and 3,546 restricted share units under the company’s long-term incentive plan.

On February 17, 2026, he sold 53,931 shares of common stock in open-market transactions at a reported price of $243.0000 per share, following option exercises at lower exercise prices. The filing also shows shares withheld at $243.4500 per share to cover tax liabilities upon RSU vesting, and his remaining common stock holdings are reported as directly owned.

Johnson & Johnson EVP and Chief Legal Officer Elizabeth Forminard reported multiple equity compensation moves. On February 15, she received 27,076 employee stock options and 1,944 restricted share units at a stated price of $0.0000 per unit. Around the same time, previously granted RSUs and performance share units vested and converted into common stock, while several hundred shares were withheld at about $243–$245 per share to cover tax obligations.

Johnson & Johnson executive Jennifer L. Taubert reported multiple equity transactions tied to long-term incentive awards. On February 13, 2026, she acquired common stock through the vesting and conversion of 1,302 Restricted Share Units and 27,412 Performance Share Units. Shares totaling 409 and 13,547 were withheld at prices of $244.55 per share to cover related tax obligations.

On February 15, 2026, she received new grants of 54,869 employee stock options and 3,940 Restricted Share Units under the company’s Long-Term Incentive Plan, and additional RSUs vested into 1,594 and 1,847 common shares. To satisfy taxes on these vestings, 816 and 945 shares were withheld at $243.45 per share. After these transactions, she continued to hold a substantial number of Johnson & Johnson common shares directly.

Timothy Schmid, EVP and Worldwide Chair, MedTech at Johnson & Johnson, reported a series of equity award exercises, sales, and new grants. He sold 22,623 shares of Common Stock in open-market transactions around $244 per share on February 18, 2026 after exercising employee stock options.

Earlier in February, Schmid acquired shares through the vesting and conversion of Restricted Share Units and Performance Share Units, with some shares withheld to cover taxes as noted in the Long-Term Incentive Plan footnotes. On February 15, 2026, he received new grants of 35,489 employee stock options and 2,548 Restricted Share Units.

Following these transactions, Schmid directly held 26,769 shares of Common Stock, plus indirect holdings of 745 shares via a 401(k) and 46 shares via an ESOP as of the plans’ most recent reporting date.

JOHNSON & JOHNSON CEO and Chairman Joaquin Duato reported multiple equity transactions related to the company’s long-term incentive plan. On February 15, 2026, he received a grant of 131,734 employee stock options and 9,459 restricted share units, each representing the right to receive one share of common stock upon vesting.

Across February 13 and 15, 2026, previously awarded RSUs and performance share units vested and were converted into common stock through several exercises coded “M”. In connection with these vestings, common shares coded “F” were withheld at prices around $243.45–$244.55 per share to satisfy tax obligations. Duato also reports indirect holdings of 998 common shares through a 401(k) plan and 30,852 shares held by his spouse.

Johnson & Johnson executive Vanessa Broadhurst, EVP of Global Corporate Affairs, reported several equity transactions. On February 17, 2026, she completed an open-market sale of 6,197 shares of Common Stock at a weighted average price of $243.39 per share, leaving her with 23,003 shares of common stock held directly.

On February 13 and 15, 2026, previously granted Restricted Share Units (RSUs) and Performance Share Units (PSUs) vested and were converted into common shares, with a portion of those shares withheld to cover tax obligations. The filing also shows new equity awards under Johnson & Johnson’s Long-Term Incentive Plan, including 14,405 employee stock options and additional RSUs that generally vest in three equal annual installments beginning on the first anniversary of their grant dates.

Johnson & Johnson executive Joseph J. Wolk, Exec VP and CFO, was granted 37,463 Performance Share Units on February 9, 2026. These PSUs were awarded under the company’s Long-Term Incentive Plan tied to a grant originally made on February 13, 2023.

The PSUs convert into shares of common stock upon vesting. The 37,463 units reflect the target award adjusted based on achievement of performance conditions in the award agreement, which were certified on February 9, 2026. Following this transaction, Wolk directly holds 37,463 derivative securities.

Johnson & Johnson executive Jennifer Taubert reported an equity award tied to performance. On February 9, 2026, she acquired 27,412 Performance Share Units (PSUs) at a price of $0. These PSUs were originally granted on February 13, 2023 under the company’s Long-Term Incentive Plan.

The 27,412 PSUs represent the target award adjusted based on achievement of performance conditions, which were certified on February 9, 2026. The PSUs convert into shares of Johnson & Johnson common stock upon vesting, so their ultimate value depends on both vesting and the company’s share price at that time.

Johnson & Johnson executive James D. Swanson, EVP and CIO, reported an equity award tied to prior performance. On February 9, 2026, he acquired 9,412 Performance Share Units at a price of $0.00 per unit. These PSUs were originally granted under the company’s Long-Term Incentive Plan on February 13, 2023 and convert into shares of common stock upon vesting.

The 9,412-unit amount reflects the target PSUs from the 2023 grant, adjusted based on achievement of the performance conditions specified in the award agreement, which were certified on February 9, 2026. Following this transaction, Swanson directly holds 9,412 derivative securities in the form of these PSUs.

Johnson & Johnson executive Timothy Schmid reported an equity award tied to performance. On February 9, 2026, he acquired 4,378 Performance Share Units at a price of $0 under the company’s long-term incentive plan. These units were originally granted on February 13, 2023.

The PSUs convert into shares of Johnson & Johnson common stock upon vesting. The 4,378-unit amount reflects the target number from the original grant, adjusted based on achievement of performance conditions that were certified on February 9, 2026. Following this transaction, Schmid directly holds 4,378 derivative securities related to common stock.

Johnson & Johnson executive Kristen Mulholland, EVP and Chief HR Officer, acquired 3,602 Performance Share Units (PSUs) on February 9, 2026. These PSUs were originally granted on February 13, 2023 under the company’s Long-Term Incentive Plan and convert into shares of common stock upon vesting.

The 3,602 PSUs reflect the target award adjusted based on certified achievement of the performance conditions in the award agreement as of February 9, 2026. Following this transaction, Mulholland directly holds 3,602 derivative securities tied to Johnson & Johnson common stock.

Johnson & Johnson reported that EVP and Chief Legal Officer Elizabeth Forminard acquired 13,706 Performance Share Units (PSUs) on February 9, 2026 as a grant under the company’s long-term incentive plan.

The PSUs, originally granted on February 13, 2023, convert into an equal number of Johnson & Johnson common shares upon vesting, with the final number certified based on achievement of performance conditions as of February 9, 2026.

Johnson & Johnson CEO and Chairman Joaquin Duato reported receiving an equity award tied to company performance. On February 9, 2026, he acquired 73,054 Performance Share Units (PSUs) at a price of $0 per unit. These PSUs were originally granted on February 13, 2023 under the long-term incentive plan and convert into an equal number of Johnson & Johnson common shares upon vesting, based on performance conditions that were certified on February 9, 2026.

Johnson & Johnson executive equity award: Vice President and Corporate Controller Robert J. Decker acquired 2,741 Performance Share Units (PSUs) on February 9, 2026 as a grant under the company’s long-term incentive plan. These PSUs were originally granted on February 13, 2023 and convert into shares of common stock upon vesting, with the final number reflecting certified achievement of performance conditions.

Johnson & Johnson executive Kathryn E. Wengel reported an equity award tied to company performance. On February 9, 2026, she acquired 13,706 Performance Share Units at a price of $0 under Johnson & Johnson’s long-term incentive plan.

The PSUs were originally granted on February 13, 2023 and convert into shares of common stock when they vest. The 13,706 units represent the target grant amount adjusted based on achievement of the performance conditions specified in the award agreement, as certified on February 9, 2026. Following this transaction, she directly holds 13,706 derivative securities in the form of PSUs.